Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Current Assets (2020 - 2025)

Historic Current Assets for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $328.2 million.

  • Lyell Immunopharma's Current Assets fell 2707.37% to $328.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $328.2 million, marking a year-over-year decrease of 2707.37%. This contributed to the annual value of $379.6 million for FY2024, which is 3156.6% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Current Assets of $328.2 million as of Q3 2025, which was down 2707.37% from $282.2 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Current Assets high stood at $834.8 million for Q2 2021, and its period low was $282.2 million during Q2 2025.
  • Its 5-year average for Current Assets is $547.3 million, with a median of $596.6 million in 2023.
  • Per our database at Business Quant, Lyell Immunopharma's Current Assets skyrocketed by 453.11% in 2022 and then plummeted by 4353.73% in 2025.
  • Lyell Immunopharma's Current Assets (Quarter) stood at $626.3 million in 2021, then increased by 3.99% to $651.3 million in 2022, then decreased by 14.83% to $554.7 million in 2023, then tumbled by 31.57% to $379.6 million in 2024, then decreased by 13.54% to $328.2 million in 2025.
  • Its Current Assets was $328.2 million in Q3 2025, compared to $282.2 million in Q2 2025 and $309.2 million in Q1 2025.